Artigos

Brazilian Position Statement on the Use Of Multimodality Imaging in Cardio-Oncology – 2021Realização: Departamento de Imagem Cardiovascular (DIC) da Sociedade Brasileira de Cardiologia (SBC) eendossado pela Sociedad Interamericanana de Imágenes Cardiovasculares (SiSIAC) da Sociedad Interamericanade Cardiología (SIAC)Conselho de Normatizações e Diretrizes (2020-2021): Brivaldo Markman Filho, Antonio Carlos Sobral Sousa,Aurora Felice Castro Issa, Bruno Ramos Nascimento, […]

Position Statement on the Use of Myocardial Strain in Cardiology Routines by the BrazilianSociety of Cardiology’s Department Of Cardiovascular Imaging – 2023Realização: Departamento de Imagem Cardiovascular da Sociedade Brasileira de Cardiologia (DIC/SBC) Almeida ALC, Melo MDT, Bihan DCSL, Vieira MLC, Pena JLB, Castillo JMD, Abensur H, et al. Posicionamento do Departamento de Imagem Cardiovascular da

Cardiac amyloidosis is a classic example of an infiltrativedisease whose predominant phenotype is characterized by ahypertrophic pattern of myocardial involvement.¹,² The mostrelevant studies—both those focused on the development ofdisease-modifying therapies and cohorts evaluating diagnostictools—have used increased ventricular wall thickness as akey criterion for suspecting cardiac amyloidosis.1-6 Based onthis concept, several diagnostic algorithms have proposedventricular wall

Background The diagnosis of cardiac amyloidosis (CA) ischallenging owing to vague symptomatology and nonspecific echocardiographic findings.Objective To describe regional patterns in longitudinalstrain (LS) using two-dimensional speckle-trackingechocardiography in CA and to test the hypothesis thatregional differences would help differentiate CA fromother causes of increased left ventricular (LV) wallthickness.Methods and results 55 consecutive patients with CAwere compared

Recent-onset cardiomyopathy represents a clinically dynamic and potentially reversible clinical framework of non-ischaemiccardiomyopathy, characterized by high variability in left ventricular (LV) function and arrhythmic risk. This clinical consensusstatement provides a structured diagnostic and therapeutic approach based on two prognostic axes: the potential for LV reverse remodelling (LVRR) and the risk of sudden cardiac death (SCD).

Technetium-99m bone scintigraphy has revolutionized the non-invasive diagnosis oftransthyretin cardiac amyloidosis (ATTR-CM) and markedly increased disease recognition.Although this technique should ideally be applied in patients with a high pre-test probability of ATTR-CM, its use in other clinical settings may reveal incidental pathologicalmyocardial uptake that prompts referral to specialized centers even in the absence of typicalred

Cardiac amyloidosis represents a unique disease process characterized by amyloid fibril deposition within the myocardialextracellular space. Advances in multimodality cardiac imaging enable accurate diagnosis and facilitate prompt initiationof disease-modifying therapies. Furthermore, rapid advances in multimodality imaging have enriched understanding ofthe underlying pathogenesis, enhanced prognostication, and resulted in the development of imaging-based markers thatreflect the amyloid

Aims Tafamidis is an approved treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) basedon the 30-month Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). This post-hoc analysisevaluated outcomes in ATTR-ACT and its long-term extension study (LTE) by baseline National AmyloidosisCentre (NAC) stage. …………………………………………………………………………………………………………………………………………………Methodsand resultsPatients received either the approved dose of tafamidis 80 mg or placebo in

IMPORTANCE Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disordercaused by destabilization of serum transthyretin (sTTR). Acoramidis, an approved therapythat achieves near-complete (90%) sTTR stabilization, demonstrated clinical benefitthrough month 30 in ATTRibute-CM, which was incremental through month 42 in theopen-label extension (OLE); however, the longer-term durability of outcomes has not beenreported.OBJECTIVE To evaluate the long-term efficacy

BACKGROUNDTransthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fataldisease. Vutrisiran, a subcutaneously administered RNA interference therapeuticagent, inhibits the production of hepatic transthyretin.METHODSIn this double-blind, randomized trial, we assigned patients with ATTR-CM in a 1:1ratio to receive vutrisiran (25 mg) or placebo every 12 weeks for up to 36 months.The primary end point was a composite